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Clinical data and experimental studies have suggested a relationship between psycho-
social factors and cancer prognosis. Both, stress effects on the immune system and on 
tumor biology were analyzed independently. However, there are few studies regarding 
the stress influence on the interplay between the immune system and tumor biology. 
Moreover, antidepressants have been used in patients with cancer to alleviate mood 
disorders. Nevertheless, there is contradictory evidence about their action on cancer 
prognosis. In this context, we investigated the effect of chronic stress on tumor progres-
sion taking into account both its influence on the immune system and on tumor biology. 
Furthermore, we analyzed the action of selective serotonin reuptake inhibitors, fluoxetine 
and sertraline, in these effects. For this purpose, C57BL/6J mice submitted or not to a 
chronic stress model and treated or not with fluoxetine or sertraline were subcutaneously 
inoculated with EL4 cells to develop solid tumors. Our results indicated that chronic 
stress leads to an increase in both tumor growth and tumor cell dissemination. The 
analysis of cell cycle regulatory proteins showed that stress induced an increase in the 
mRNA levels of cyclins A2, D1, and D3 and a decrease in mRNA levels of cell cycle 
inhibitors p15, p16, p21, p27, stimulating cell cycle progression. Moreover, an augment 
of mRNA levels of metalloproteases (MMP-2 and MMP-9), a decrease of inhibitors of 
metalloproteases mRNA levels (TIMP 1, 2, and 3), and an increase in migration ability were 
found in tumors from stressed animals. In addition, a significant decrease of antitumor 
immune response in animals under stress was found. Adoptive lymphoid cell transfer 
experiments indicated that the reduced immune response in stressed animals influenced 
both the tumor growth and the metastatic capacity of tumor cells. Finally, we found an 
important beneficious effect of fluoxetine or sertraline treatment on cancer progression. 
Our results emphasize the crucial role of the immune system in tumor progression under 
stress situations. Although a direct effect of stress and drug treatment on tumor biology 
could not be ruled out, the beneficial effect of fluoxetine and sertraline appears to be 
mainly due to a restoration of antitumor immune response.
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inTrODUcTiOn
Nowadays, stress affects thousands of people around the world. 
Stress is defined as a critical, real, or apparent, situation that rep­
resents a challenge for homeostasis. To restore this state, a coor­
dinated adaptive response is triggered. Stress mediators involve 
not only catecholamines and glucocorticoids (the characteristic 
neuroendocrine hormones of the stress response) but also several 
other neurotransmitters, cytokines, and growth factors (1). It is 
important to note that although stress response is an essential 
survival mechanism, when it is prolonged over time, may affect 
endocrine, immunological, and behavioral function (1). In par­
ticular, epidemiological studies indicate that chronic stress might 
constitute a risk factor for cancer onset and progression (2, 3).
The role of psychosocial factors in cancer initiation is ambi­
guous. However, the influence of stress on cancer progression has 
been demonstrated. Both clinical and experimental studies have 
shown that the mechanisms involved in stress response are capa­
ble of influencing processes related to cancer progression (4–6). 
Animal models that mimic the pattern of human disease have 
been used to understand the impact of stress on cancer and other 
pathologies. These studies put the main focus on the neuroendo­
crine modulation of the immune response to tumor cells (2, 7–10). 
Moreover, the direct effect of stress mediators on the proliferation 
and aggressive behavior of tumor cells, independently of the 
influence on the immune system, has been analyzed. The group 
of Sood demonstrated that chronic stress increase catecholamine 
levels in tumors that in turn promote metastasis of breast (11) 
and ovarian (12) carcinomas. In addition, in many experimental 
models, the biological consequences of stress have been shown 
to be reverted by β­adrenergic blockers (11). In addition, it was 
proposed that norepinephrine also promotes resistance to anoikis, 
inhibits apoptosis, and increases chemoresistance (13) of tumor 
cells. Nevertheless, in general, these studies were developed in 
athymic nude or SCID mice and analyze the influence of stress 
on tumor invasion and metastasis independently of the action 
of immune system (14).
In addition, selective serotonin reuptake inhibitors (SSRIs), 
as fluoxetine and sertraline, are frequently prescribed for the 
treatment of stress­associated disorders, such as depression, 
obsessive–compulsive disorder, panic attack, and bulimia nervosa. 
The use of antidepressants has been related to immune alterations. 
Nevertheless, conflictive data have been reported regarding the 
impact of fluoxetine on the immune system and cancer prognosis 
(15). In a previous report, we showed that fluoxetine reverts the 
effect of stress on T helper immunity through compensatory and/
or specific mechanisms (16). In addition, fluoxetine was able to 
enhance the apoptosis/proliferation balance of lymphoma cells 
and increase T cell immunity in tumor­bearing mice (17).
In this context, the objective of this study was to investigate the 
effect of chronic stress on tumor progression taking into account 
both its influence on the immune system and its action on tumor 
biology. Moreover, we aimed to analyze the influence of two 
SSRIs, fluoxetine and sertraline, in these effects. For this purpose, 
we used EL4 T cell lymphoma cells growing as a solid tumor in 
C57BL/6J mice submitted or not to a variable stress model and 
treated or not with fluoxetine or sertraline. Our results indicate 
that tumor growth and metastases are affected by psychological 
stress. Cellular adoptive transfer approach pointed out that 
changes in tumor biology were predominantly the result of the 
influence of stress on the immune function. In addition, treat­
ment with the SSRIs, fluoxetine and sertraline, prevented these 
effects. These findings strengthen the clinical research about the 
beneficial effects of the SSRIs prescription in cancer patients.
MaTerials anD MeThODs
cell line and culture condition
The tumor cell line EL4 was obtained from American Type Cul­
ture Collection (ATCC, Manassas, VA, USA; Catalog Number 
TIB­39). Cells were cultured in RPMI 1640 with 10% fetal bovine 
serum (GIBCO). EL4 cell line was established from a lymphoma 
induced in a C57BL/6J mouse by 9,10­dimethyl­1,2­benzan­
thracene (18). Cells were cultured at an optimal concentration 
(1–5 × 105 cells/ml) in RPMI­1640 medium supplemented with 
10% v/v fetal bovine serum, 2 mmol/l glutamine, and 100 mg/
ml streptomycin (all from Life Technologies), at 37°C in 5% CO2 
atmosphere, as previously described (19).
animals
Inbred female C57BL/6J (H­2b) mice, 2–3 months old, were bred 
and kept at the Instituto de Investigaciones Biomédicas (BIOMED, 
CONICET­UCA, Buenos Aires, Argentina). Animals were cared 
for and sacrificed according to the rules of the “Guide for the Care 
and Use of Laboratory Animals” (NIH) (revision 2011) and to 
the EC Directive 86/609/EEC (revision 2010). The experimental 
protocol was also approved by the local Institutional Committee 
for the Use and Care of Laboratory Animal rules (CICUAL, 
BIOMED, Argentina).
chronic stress Model and ssris 
administration Protocol
The chronic stress model used consists in the aleatory, intermit­
tent, and unpredictable exposure to different stressors during 
5 weeks in C57BL/6J mice. Briefly, animals were randomly and 
alternately exposed to one of the following stressors for the time 
indicated for each assay: restraint in well­ventilated tubes for 6 h 
(20), tail suspension for 5 min (21), forced swimming for 5 min 
(22), cold temperature exposure (4°C) for 2 h (23, 24), and 2 days 
of continuous overnight illumination (25).
To analyze the effect of SSRIs, mice were orally given 15 mg/kg/day 
of fluoxetine (Sigma­Aldrich) (26) or 20 mg/kg/day of sertraline 
(Sigma­Aldrich) (27), in a fresh solution prepared in the drinking 
water. The preparation of these solutions was performed taking 
into account the volume of water drunk daily by each mouse 
(5 ml) to reach the indicated dose.
lymphoma Model and Tumor growth
C57BL/6J syngeneic animals, under different treatments, received 
subcutaneous injections of 3 × 105 EL4 cells in 200 µl of phosphate­
buffered solution (PBS) to generate a solid tumor. Tumor length 
and width were measured every day using calipers, and tumor 
volume was calculated as V = π/6 × length × width (7). With the 
TaBle 1 | Primers sequences for quantitative real-time reverse transcription polymerase chain reaction.
gene accession no. sequences amplicon size (pb) annealing T (°c)
Cyclin A2 NM_009828.2 Fw: 5′-GGCCAGCTGAGCTTAAAGAAAC-3′
Rv: 5′-CGGGTAAAGAGACAGCTGCAT-3′
69 61
Cyclin D1 NM_007631.2 Fw: 5′-CCAAAACCATTCCATTTCAAAG-3′
Rv: 5′-CCAACACACACCAGCAACACT-3′
68 61
Cyclin D3 NM_007632.2 Fw: 5′-TGCGTGCAAAAGGAGATCAA-3′
Rv: 5′-TCACACACCTCCAGCATCCA-3′
68 60
p15/INK4B NM_007670.4 Fw: 5′-TGGGAAACCTGGAGAGTAGATGA-3′
Rv: 5′-GAATCCCCACACATGACAGTACA-3′
66 58
p16/INK4A NM_009877.2 Fw: 5′-CTCAACTACGGTGCAGATTCGA-3′
Rv: 5′-CACCGGGCGGGAGAA-3′
57 58
p21/Cip1 NM_007669.5 Fw: 5′-TGTGGCTCCCTCCCTGTCT-3′
Rv: 5′-GCAGGGTGCTGTCCCTTCT-3′
63 58
p27/Kip1 NM_009875.4 Fw: 5′-CCTGGCTCTGCTCCATTTGA-3′
Rv: 5′-ACGGATGGAGCGCAAAAC-3′
71 58
MMP-2 NM_008610.3 Fw: 5′-TCTGGTGCTCCACCACATACAACT-3′
Rv: 5′-CTGCATTGCCACCCATGGTAAACA-3′
90 60
MMP-9 NM_013599.4 Fw: 5′-TGAACAAGGTGGACCATGAGGTGA-3′
Rv: 5′-TAGAGACTTGCACTGCACGGTTGA-3′
121 60
Timp-1 NM_001044384.1 Fw: 5′-GGTGTGCACAGTGTTTCCCTGTTT-3′
Rv: 5′-AAGCAAAGTGACGGCTCTGGTAGT-3′
119 60
Timp-2 NM_011594.3 Fw: 5′-TTTCTAGCCACACCAGGCAGATGA-3′
Rv: 5′-GGTTTGCTGGGAAGGCATTTGAGT-3′
112 60
Timp-3 NM_011595.2 Fw: 5′-ACCACTGCTTTGTCCAGGTGTTTG-3′
Rv: 5′-ATGGAAATGGTTGTGCCTTCTGCC-3′
145 64
β2-microglobulin NM_009735.3 Fw: 5′-GCTATCCAGAAAACCCCTCAA-3′
Rv: 5′-CATGTCTCGATCCCAGTAGACGGT-3′
300 58
Cyclophilin B NM_011149.2 Fw: 5′-CGAGTCGTCTTTGGACTCTTT-3′
Rv: 5′-GCCAAATCCTTTCTCTCCTGTA-3′
87 58
G6PDH NM_008062.2 Fw: 5′-GAAGCTGCCAATGGATACTTAGA-3′
Rv: 5′-CCACCGTTCATTCTCCACATAG-3′
99 58
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exception of mice used for the spontaneous metastasis test, mice 
were euthanized by CO2 overexposure 14 days post tumor cell 
injection or when tumor reached the maximum volume allowed 
by ethical standards (Guidelines for Endpoints in Animal Study 
Proposals, NIH).
Quantitative real-Time reverse 
Transcription Polymerase chain  
reaction (qrT-Pcr)
After 14 days of tumor injection, animals were sacrificed, solid 
tumors were dissected and instantly homogenized in Tri­Reagent 
(Genbiotech SRL) to isolate the RNA, following the manu­
facturer’s instructions. The RNA pellets were re­suspended in 
RNase­free water, and the RNA concentration was quantified by 
measuring the absorbance at 260 nm in a nanodrop (Nanodrop 
ND­1000, Thermo Fisher Scientific Inc.). The total RNA was 
used as a template to generate first­strand cDNA synthesis using 
the M­MLV Reverse Transcriptase (Invitrogen), random prim­
ers (Invitrogen), and dNTPs (Invitrogen). The cDNA amounts 
present in each sample were determined by a 7500 Real­Time 
PCR System (Applied Biosystems) using the KAPA SYBR® 
FAST qPCR Kit Master Mix (2×) Universal (Kapa Biosystems) 
and following the manufacturer’s instructions. Each RT­PCR 
quantification experiment was performed in duplicate. To verify 
that the SYBR Green dye detected only one PCR product, all the 
reactions were subjected to a heat dissociation protocol following 
the final cycle of PCR. The sequences of mouse­specific primers, 
the annealing temperature, and the amplicon size are provided 
in Table  1. The primer sequences (Biodynamics SRL), shown 
in Table  1, were designed using the Primer Express Software 
version 3.0 (Applied Biosystems). To determine the target gene 
mRNA expression, the comparative cycle threshold (Ct) method 
was used (28). An average Ct value was calculated from the dupli­
cate reactions and normalized to the expression of β2­microglo­
bulin, and the 2(−ΔΔCt) value was calculated. It is important 
to note that similar results were obtained using cyclophilin or 
glucose­6­phosphate­dehydrogenase (G6PDH) mRNA expres­
sion levels as housekeeping (data not shown) (29).
Disaggregation of solid Tumor
After 14 days of tumor injection, mice were sacrificed, and solid 
tumors were dissected. To obtain cells from solid tumors, a modi­
fication of conventional method of disaggregation by trypsinisa­
tion was used (30). Briefly, tumors were fragmented and were 
FigUre 1 | Effect of fluoxetine and sertraline on stress-induced tumor progression. (a) Schematic representation of experimental protocol. C57BL/6J mice were 
treated either with (S) or without (C) the chronic stress protocol, and with or without (VEH) fluoxetine or sertraline. Five weeks later, 3 × 106 EL4 cells were 
subcutaneously injected to generate solid tumors. Two weeks post injection (p.i.), mice were sacrificed. (B) Time course of tumor volume for the different 
experimental groups. (c) Tumor weight at day 14 post EL4 cells injection. Values are expressed as mean ± SEM. n = 6 mice per group. *p < 0.05; **p < 0.01 
respect to control mice.
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incubated at 37°C for 30 min with a solution containing 0.25% 
trypsin and 0.004% of DNAse in PBS in a relation of 10 ml per 
1 ml of tissue. After incubation, the trypsin solution containing 
dissociated cells was collected into a sterile 50­ml centrifuge tube. 
Immediately, an equal volume of RPMI medium containing 10% 
FBS was added to inactivate the trypsin and protect the cells from 
continued proteolytic digestion. The cell suspension was centri­
fuged for 5 min at 400 g and re­suspended in culture medium. 
This procedure was repeated two times to obtain the optimal 
tissue disaggregation. Cell viability was checked by trypan blue 
exclusion test and settled to the desired concentration.
evaluation of Metastatic Properties of 
Tumor cells
To analyze the metastatic properties of tumor cells, spontaneous 
and experimental metastasis assays were used (31). One group of 
solid tumor­bearing mice was used for spontaneous metastasis 
assessment. These mice were monitored every day and were 
euthanized when they exhibited characteristic of animals that are 
about to die such as signs of suffering, hypothermia, and slow 
locomotion. Animals were sacrificed at day 19 post EL4 cells 
subcutaneous injection, and the number of metastatic nodules 
in kidney and liver was determined. For the experimental meta­
stasis tests, mice were inoculated through the tail vein either with 
5 × 105 EL4 cells or with solid tumor disaggregated cells from the 
different experimental groups. After 14 days, mice were killed, 
organs were removed, and metastatic nodules were counted.
Migration assay
Tumors from mice of different experimental groups were disag­
gregated as described in Section “Disaggregation of Solid Tumor” 
and 5 ×  104 cells of each tumor were re­suspended in RPMI 
culture medium without FBS, seeded into the top well of a 
transwell chamber with 8.0­µm pores (Jet Biofil), and allowed to 
migrate toward medium containing 10% of FBS for 24 h. Cells in 
the upper and in the lower compartment were counted using a 
Neubauer chamber. Cell migration is presented as percentage of 
total cell count for each sample (32).
natural Killer activity assay
YAC­1 cells were acquired from ATCC (Catalog number TIB­160). 
Cells were maintained in supplemented medium as described 
for EL4 cells. Specific cytotoxic activity against tumor cells was 
determined according to the just another method (JAM method) 
as previously reported (7). Briefly, YAC­1 cells were cultured 
in the presence of 5 mCi [3H]­thymidine for 16 h. Cell suspen­
sions from spleens of mice from different groups were obtained. 
Briefly, spleens were removed and disrupted through a 1­mm 
metal mesh, and the cell suspensions were filtered through a 
10­lm nylon mesh. The suspensions were depleted of red blood 
and dead cells using a lysis buffer (NH4Cl 8.29  g, KHCO3 1  g, 
EDTA­2Na 37.2 mg, diluted in distilled water, at pH = 7.4) for 
2  min. After three washes in PBS, cells were re­suspended in 
PBS at final concentration. Cell viability was assessed by trypan 
blue exclusion assay. A target:effector ratio 1:50 was seeded in 
96­well plates at a final volume of 200 µl, and incubated for 3.5 h 
FigUre 2 | Effect of chronic stress on the expression of proteins associated with cell cycle progression. Action of fluoxetine or sertraline treatment. Quantitative 
real-time reverse transcription polymerase chain reaction was performed in cDNA obtained from solid tumors excised 14 days post EL4 cells inoculation. (a) Cyclin 
A2, (B) D1, (c) D3, CDKIs (D) p15/Ink4b, (e) p16/Ink4a, (F) p21/Cip1, and (g) p27/Kip1 mRNA relative expression was quantified using β2-microglobulin as 
housekeeper. Values are expressed as mean ± SEM. n = 6 mice per group. **p < 0.01, ***p < 0.001 respect to control mice.
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at 37°C in a 5% CO2 atmosphere. [3H]­Thymidine incorporation 
was measured by scintillation counting after retention over GF/C 
glass­fiber filters (Whatman). NK activity was calculated as 
100 × (SR − ER)/SR, where SR is the spontaneous release and ER 
is the experimental release.
cytotoxic activity assays
Specific cytotoxic activity against tumor cells was evaluated 
according to the JAM test (7) as previously described. Briefly, EL4 
labeled overnight with 5 mCi [3H]­thymidine were co­cultured 
with spleen cell suspensions from tumor­bearing mice from the 
different treatments at a target:effector ratio of 1:15 for 3.5 h. The 
percentages of cytotoxic activity were calculated as the following 
relation: cytotoxic activity of T lymphocytes = 100 × (SR − ER)/
SR, where SR is the spontaneous release and ER is the experi­
mental release.
Total-Body γ-irradiation and lymphoid 
cell Transplantation
Two­month­old C57BL/6J mice were placed individually into 
1­mm thick, rectangular plastic boxes (30 mm × 30 mm × 60 mm) 
with holes to allow free exchange of air. Mice were exposed to a 
FigUre 3 | Experimental metastasis assay using EL4 cells. Experimental 
metastasis were evaluated 14 days after intravenous tail injection of 5 × 105 
EL4 cells in mice subjected (S) or not (C) to chronic stress treatment.  
(a) Schematic representation of experimental protocol. Percentage of mice 
with metastatic nodules in kidney (B) or liver (D) was calculated. Number of 
metastatic nodules in kidney (c) or liver (e) was assessed. Results are the 
mean ± SEM of three independent experiments (n = 4 mice per group).
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comparing two proportions was used to analyze the statistical 
significance of % mice with spontaneous metastasis. p < 0.05 was 
considered to indicate a statistically significant difference.
resUlTs
Fluoxetine and sertraline are able to 
Prevent the Promotion of el4 lymphoma 
growth induced by chronic stress
To investigate the effect of chronic stress on tumor growth, 
5­week­stressed and control mice were subcutaneously inocu­
lated with EL4 syngeneic lymphoma cells to develop a solid tumor 
and tumor volume was determined every day. The stress protocol 
continued until the sacrifice of the mice. To analyze the effect of 
fluoxetine or sertraline treatment, drugs were dispensed orally 
simultaneously to stress exposure (see Figure 1A). A significant 
effect depending on time, stress exposure, and SSRIs treatment 
was found (F14,210  =  5.299; p  <  0.001). As it can be seen in 
Figure 1B, data indicated that tumor growth was accelerated in 
chronically stressed mice respect to control animals after day 13. 
Interestingly, both fluoxetine and sertraline treatments counter­
act the stress effects on tumor growth. Accordingly, tumor weight 
at day 14 post EL4 cells injection was significant depending on 
single dose of 2 Gy applied to the total body at a rate of 0.8 Gy/
min. Gamma­irradiation was performed using a vertical beam 
containing 137Cs source (Cebirsa SA, Buenos Aires, Argentina). 
This procedure provokes a lymphocyte depression near 80% (33).
On the following day, mice were transplanted with lymphoid 
cells that were obtained from mice of the different experimen­
tal groups. For this purpose, mice were sacrificed and lymph 
nodes (axillary, inguinal, and mesenteric) were obtained and 
disaggregated through a 1­mm metal mesh, and the cell sus­
pension was filtered through a 10­µm nylon mesh. After three 
washes in PBS, cells were re­suspended at final concentration 
(7). A volume of 0.1 ml of cell suspension containing 8 × 106 
lymphoid cells was transplanted into the recipients via tail vein 
injection.
Depletion of immune cells in 
Disaggregated Tumors
After 14 days of tumor injection, mice were sacrificed, and solid 
tumors were dissected. To purify tumor cells, an immune cell com­
plement depletion protocol was used (34). Noteworthy, EL4 cells 
are CD4 and CD8 negative, so lymphoma cells are not affected by 
complement­dependent antibody­mediated lysis. Briefly, tumors 
were disaggregated as explained in Section “Disaggregation of 
Solid Tumor.” The cell suspension was adjusted to 2 × 107 cells/ml 
and anti­mouse CD8a, CD4, and F4/80 (BD Biosciences) were 
added at a proper predetermined dilution. Then, cells were incu­
bated for 30 min at 4°C and centrifuged at 400 g for 5 min. The 
pellet was re­suspended in RPMI containing 10% of low toxic­
ity rabbit complement, incubated for 1  h at 37°C mixing every 
15 min, and centrifuged at 400 g for 5 min. The cell pellet was then 
re­suspended either in RPMI­1640 culture for migration assay or 
in Tri­Reagent (Genbiotech SRL) to isolate the RNA. To confirm 
the effectiveness of the depletion protocol, a flow cytometric 
analysis was performed, comparing tumor cell suspensions before 
and after depletion. Cell suspensions were incubated with CD4, 
CD8, and F40/80 conjugated antibodies. All three cell populations 
were reduced after treatment. Macrophages from 15.6 to 1.5%, 
CD8+ cells from 6.5 to 1.2%, and CD4+ cells 4.7 to 0.6%. Total 
immune cells from 26.8 to 3.3%.
statistical analysis
Data were expressed as the mean ± SEM for each group. All the 
data were processed using STATISTICA software (StatSoft, Inc., 
Tulsa, OK, USA). The normality and homogeneity of variance for 
the dataset were tested using the Shapiro–Wilk test and Levene’s 
test, respectively. Growth tumor data were analyzed with repeated 
measures two­way ANOVA analysis with condition (control or 
stressed) and pharmacological treatments (vehicle, fluoxetine, 
and sertraline) as factors. Other data were analyzed by two­way 
ANOVA with condition and pharmacological treatment as factors. 
For experiments using immune cell­depleted suspensions, one­
way ANOVA was used. In all cases, if ANOVA showed significant 
differences between groups, Fisher’s post hoc test was performed 
to determine significance level. Student’s t­test was used for two 
group comparisons. Non­parametric Mann–Whitney U test was 
carried out to compare the number of metastatic nodules found 
in control and stressed mice. The binomial distribution test for 
FigUre 4 | Experimental metastasis assay using cells from solid tumors of different experimental groups. 14 days post subcutaneous injection of EL4 cells in mice 
from different experimental groups, solid tumors were excised and disaggregated. 5 × 105 cells were injected intravenously in untreated mice. Two weeks later, mice 
were sacrificed. (a) Schematic representation of experimental protocol. Percentage of mice with metastatic nodules in kidney (B) or liver (D) was calculated. 
Number of metastatic nodules in kidney (c) or liver (e) was assessed. Results are the mean ± SEM of two independent experiments (n = 5 and 4 mice per group). 
*p < 0.05, **p < 0.01 respect to control mice.
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stress exposure and SSRIs treatment (F2,30 =  4.460; p =  0.020) 
(Figure 1C).
To ascertain if proteins involved in the regulation and prog­
ression of cell cycle could be altered in parallel with tumor 
growth, we evaluated the tumor mRNA expression of A2, D1, 
and D3 cyclins and their inhibitors p15/Ink4b, p16/Ink4a, p21/
Cip1, and p27/Kip1. Two­way ANOVA indicated that mRNA 
expression depended on stress exposure and SSRIs treatment 
(interaction stress ×  SSRIs, A2, p =  0.037; D1, p =  0.045; D3, 
p = 0.036; p15, p < 0.001; p16, p = 0.020; p21, p = 0.016; p27, 
p =  0.048). Results displayed in Figure  2 indicate that mRNA 
levels of cyclins A2, D1, and D3 were increased in tumors from 
animals under stress. In addition, their inhibitors were decreased 
in tumors from stressed animals. Moreover, both fluoxetine and 
sertraline treatments restored mRNA expression levels of these 
regulatory proteins to control values.
chronic stress increases the Tumor 
invasion capacity: effect of Fluoxetine  
and sertraline administration
To evaluate metastatic dissemination capacity of tumor cells in diffe­
rent experimental groups, we performed experimental metastasis 
tests according to two experimental designs (see Figures  3A  
and 4A). In general, intravenous injection into the tail vein results 
in lung metastasis. However, it has been reported that EL4 cells 
mainly generate liver and kidney metastasis (35–37). First, we 
analyzed EL4 cell dissemination in control and stressed mice. For 
this procedure, EL4 cells cultured in standard conditions were 
injected in the tail vein (Figure 3). As it can be seen in Figure 3, 
the number of mice that presented metastatic nodules in the liver 
and kidney was not significantly different for control and stressed 
mice (liver: t4 = 0.894, p = 0.422; kidney: t4 = 0, p = 1). Moreover, 
Mann–Whitney U test revealed no significant differences in the 
number of metastatic nodules in these organs between both groups 
(liver: U = 62, p = 0.563; kidney: U = 59, p = 0.453).
Taking into account that stress was able to modify mRNA 
expression levels of proteins that regulate tumor growth, we 
analyzed the possibility that stress exposure could modify the 
dissemination capacity of tumor cells. For this purpose, solid 
tumors from different experimental groups were dissected and 
disaggregated to obtain cell suspensions. These cells were tail 
vein injected in untreated mice (Figure  4A). Results indicate 
that the incidence in the metastasis development depended on 
stress exposure and SSRIs treatment of the injected cells, in both 
kidney and liver (interaction stress × SSRIs: F2,6 = 8.30, p = 0.018; 
FigUre 5 | Spontaneous metastasis assay in mice from different experimental groups. (a) Schematic representation of experimental protocol. 19 days post 
subcutaneous injection of EL4 cells in mice from different experimental groups, mice were sacrificed and percentage of mice with metastatic nodules in kidney  
(B) or liver (D) was calculated. Also, number of metastatic nodules in kidney (c) or liver (e) was assessed. Values are expressed as mean ± SEM. n = 5 mice per 
group. *p < 0.05 respect to control mice.
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F2,6 =  8.03, p =  0.02, respectively). Post hoc analyses indicated 
that the percentage of mice with both kidney and liver metastasis 
was significantly higher in mice injected with cells from tumor 
of stressed mice (Figures 4B,D). Non­parametric analyses of the 
number of metastatic nodules found in liver and kidney, revealed 
a greater number of metastatic nodules in mice injected with 
cells from tumor of stressed mice respect to control mice (liver, 
U = 8.5, p = 0.013; kidney, U = 10.5, p = 0.024) (Figures 4C,E).
Considering these results, we performed one experiment to 
determine spontaneous metastasis to evaluate the ability of cells to 
spread from a tumor implanted subcutaneously. For this pur pose, 
mice were sacrificed 19 days after EL4 cells subcutaneous injection 
(Figure  5A). The binomial distribution test for comparing two 
proportions showed that the percentage of mice with metastasis 
was significantly higher in the stressed mice compared to control 
mice in both liver and kidney (p = 0.047) (Figures 5B,D). Mann–
Whitney test showed a greater number of metastatic nod ules in 
stressed mice respect to control group (liver, U = 3.5, p = 0.044; 
kidney, U = 4, p = 0.050) (Figures 5C,E). Interestingly, fluoxetine 
or sertraline treatment prevented these effects.
In accordance with these results, two­way ANOVA of transwell 
migration assay data showed that the percentage of migration 
depended on stress exposure and SSRIs treatment (interaction 
stress × SSRIs, F2,23 = 7.143, p = 0.004). Post hoc analysis indicated 
that cells from tumors of stressed animals have a major migra­
tion capacity in a transwell chamber using FBS as attractant. 
As expected, fluoxetine or sertraline treatment eliminated this 
effect (Figure 6).
Altogether, these findings indicate that stress­induced altera­
tions in the biological behavior of tumors, and fluoxetine and 
sertraline were able to prevent these changes. In this context, 
invasion­related genes such as metalloprotease 2 (MMP2) and 
MMP9, and their inhibitors (TIMP 1, 2, and 3) were determined. As 
it can be seen in Figure 7, chronic stress significantly upregulated 
FigUre 6 | Effect of chronic stress and antidepressant treatment on tumor 
cells migration. (a) Schematic representation of the experimental protocol. 
14 days post subcutaneous injection of EL4 cells in mice from different 
experimental groups, solid tumors were excised and disaggregated. 5 × 104 
cells were seeded in the upper well of transwell migration chamber and RPMI 
with 10% FBS as attractant. After 24 h, cells in the upper and in the lower 
chamber were counted. (B) Cell migration is presented as percentage of total 
cell count for each sample. Values are expressed as mean ± SEM. n = 5 
mice per group. ***p < 0.001 respect to control mice.
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(interaction stress × SSRIs, F2,36 = 6.354; p = 0.004). As it can be 
seen in Figure 8D, the percentage of EL4 cell lysis was signifi­
cantly lower when EL4 cells were incubated with splenocytes from 
stressed mice compared to control mice. Once again, fluoxetine 
and sertraline treatments counteracted this effect.
Finally, to determine if alteration of antitumor immune 
responses could be involved in the promotion of tumor growth 
and tumor invasion capacity induced by stress exposure, adoptive 
transfer experiments were performed.
For this purpose, irradiated mice were tail vein injected with 
lymphoid cells from control and stressed animals treated or not with 
fluoxetine or sertraline. After this procedure, mice were inoculated 
with tumor cells and the tumor growth and spontaneous metastasis 
were determined (see scheme in Figure 9A). A significant effect 
depending on time, stress exposure and SSRIs treatment of the 
injected cells was found (F22,352 = 5.207; p < 0.001). As it can be 
seen in Figure 9B, data indicated that tumor growth was increased 
after day 16 in mice injected with lymphocytes from chronically 
stressed mice when compared with those transferred with immune 
cells from control animals. Furthermore, mice injected with 
immune cells from stressed animals treated with fluoxetine and 
sertraline did not show this effect. Accordingly, tumor weight at 
day 18 post EL4 cells injection was significant depending on stress 
exposure and SSRIs treatment of the transferred cells (F2,32 = 3.586; 
p = 0.039) (Figure 9C). In addition, the assessment of spontaneous 
metastasis indicated that animals transferred with lymphoid cells 
from stressed animals had a higher incidence of liver metastasis 
(p = 0.023) (Figure 9D) and a major number of liver metastatic 
nodules (Figure 9E) respect to animals transferred with cells from 
control animals (U = 3.5, p = 0.027). These differences were not 
significant in kidney metastasis incidence (p = 0.740) (Figure 9F) 
or number of metastatic nodules (U = 7.5, p = 0.089) (Figure 9G). 
In addition, tumors from animals that were transferred with cells 
from stressed animals that had received fluoxetine or sertraline 
administration showed a similar biological behavior than those 
transferred with cells from control animals.
experiments Using immune cell-Depleted 
Tumor cell suspensions Demonstrate 
That Molecular alterations Observed in 
the Total Tumor Mass are Mainly due to 
changes in the cancer cells
To further ascertain whether the alterations in cell cycle gene 
expression, cell migration, and MMPs expression described above 
were originated by the direct effect of treatment on cancer cells, or 
if the immune cells present in the tumor microenvironment were 
responsible for these changes, molecular alterations were assessed 
in immune cell­depleted tumor cell suspensions.
One­way ANOVA showed significant differences between 
groups for cyclin A2 (F2,14 = 7.483; p = 0.008), D1 (F2,14 = 6.519; 
p = 0.012), and p16 (F2,14 = 4.437; p = 0.036) expression levels. 
Results displayed in Table 2 indicate that mRNA levels of cyclins 
A2, D1 were significantly increased and p16 decreased in immune 
cell­depleted suspensions from animals under stress. Treatment 
with fluoxetine prevented these changes.
the expression of MMP2 and 9 in tumors and downregulated the 
expression of TIMPs. Also, fluoxetine and sertraline impeded 
these effects (interaction stress  ×  SSRIs: MMP­2, p  =  8.079; 
MMP­9, p < 0.001; TIMP­1, p < 0.001; TIMP­2, p = 0.005; TIMP­3, 
 p = 0.046).
Fluoxetine or sertraline administration 
Prevents the Decrease of  
antitumor immune response  
induced by chronic stress
To investigate if stress exposure and drug treatment affect anti­
tumor immune responses, we evaluated the NK activity in mice 
that were not exposed to the tumor challenge (Figure 8A) and 
the specific cytotoxicity against EL4 cells in tumor­bearing mice 
(Figure  8C). Two­way ANOVA of NK activity data revealed 
that the % of lysis of YAC­1 cells depended on stress exposure 
and SSRIs treatment (interaction stress ×  SSRIs, F2,16 =  4.008, 
p = 0.039). As it is shown in Figure 8B, splenocytes from stressed 
mice showed a decreased cytotoxic activity mediated by NK cells. 
This impaired NK activity was prevented by fluoxetine and sertra­
line administration. Two­way ANOVA of the specific cytotoxicity 
assay showed that immune cells from spleens of tumor­bearing 
animals of the different experimental groups were able to lyse 
the EL4 cells depending on stress exposure and SSRIs treatment 
FigUre 7 | Effect of chronic stress on the expression of proteins associated with cell invasion. Action of fluoxetine and sertraline. Quantitative real-time reverse 
transcription polymerase chain reaction was performed in cDNA obtained from solid tumors excised 14 days post EL4 cells inoculation. (a) MMP-2, (B) MMP-9  
and their inhibitors (c) TIMP-1, (D) TIMP-2, and (e) TIMP-3 mRNA relative expression was quantified using β2-microglobulin as housekeeper. Values are expressed 
as mean ± SEM. n = 6 mice per group. **p < 0.01; ***p < 0.001 respect to control mice.
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Similarly, significant differences between groups were found 
for MMP­2 (F2,14 =  5.151; p =  0.024), MMP­9 (F2,14 =  5.826; 
p = 0.017), and TIMP­1 (F2,14 = 7.627; p = 0.007) mRNA expres­
sion. Post hoc analysis indicated a significant increase in MMPs 
and a decrease in TIMP­1 levels induced by stress that were not 
observed in stressed animals treated with fluoxetine (Table 2).
In accordance with these results, one­way ANOVA of transwell 
migration assay data showed that the percentage of migration was 
significantly different depending on the treatment (F2,14 = 5.199; 
p = 0.024). Post hoc analysis indicated that immune cell­depleted 
suspensions from stressed animals have a greater migration 
capacity in a transwell chamber using FBS as attractant. Again, 
fluoxetine treatment impeded this effect (Table 2).
DiscUssiOn
Epidemiologic and experimental animal research have indicated 
that stress may influence tumor progression (2–4, 7). However, 
the biological interactions between mediators of stress response, 
immune system, and tumor biology are not well understood. In 
particular, the role of the immune system in controlling solid 
tumor growth and dissemination has been considered unclear. 
In this context, our results showed a relevant role of antitumor 
immunity in solid tumor growth and in the invasion and dissemi­
nation of tumor cells. Our results indicated that chronic stress 
induces an alteration of immune homeostasis that in turn leads to 
an increase in both tumor growth and tumor cell dissemination. 
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In addition, an important beneficious effect of fluoxetine or sert­
raline treatment was found.
Chronic stress exposure resulted in an increase of tumor growth. 
This effect was related to an enhancement of cell cycle progres­
sion through the modulation of cell cycle regulatory proteins. We 
observed an increase in the mRNA levels of cyclins A2, D1, and D3 
in the tumors from stressed animals. A decrease in mRNA levels of 
cell cycle inhibitors p15/Ink4b, p16/Ink4a, p21/Cip1, and p27/Kip1 
was also found. Much evidence have pointed the involvement of 
cyclins D1 and D3 in T­cell lymphomagenesis, and they have been 
highlighted as relevant molecular markers of oncogenic power in 
T cell lymphomas (38, 39). In addition, an increase of cyclin D3 has 
been linked to a high proliferation rate and with reduced levels of 
p27/Kip1 (40). Cyclins D1 and D3 upregulation has been related to 
a poor outcome in lymphoma bearing patients (41–43).
A robust correlation between a big tumor load, higher tumor 
growth, and increased chance of metastasis has been demonstrated 
in many human cancers (44, 45). In accordance with this associa­
tion, our results showed an important increase of the incidence 
and number of spontaneous metastasis in stressed animals. In 
addition, we analyzed experimental metastases after intravenous 
injection into the lateral tail vein. Our results indicated that no 
differences were found in the incidence and number of nodules 
in the kidney and liver when control and stressed animals were 
injected with EL4 cells from culture. However, when untreated 
animals were injected with cells obtained from tumors that had 
been grown in stressed animals, the incidence and number of 
metastatic nodules were significantly higher than those obtained 
when injecting cells from tumors that had been dissected from 
control animals. These results indicate that stress modifies the 
capacity of cells to give metastatic colonization in distant tissues.
To metastasize, cancer cells have to migrate, overpass the extra­
cellular matrix (ECM), invade blood vessels, adhere to a remote 
place, and extravasate to originate a distant foci. MMPs are a 
zinc­dependent endopeptidases family that are able of disrupting 
the main components of the ECM and that have a relevant role in 
pathological situations that course with a significant degradation 
of ECM, such as tumor invasion, and tumor metastasis (46). In 
FigUre 8 | Influence of chronic stress and antidepressant treatment on antitumor immunity. (a) Schematic representation of experimental protocol. Mice were 
treated either with (S) or without (C) the chronic stress protocol, and with or without (VEH) fluoxetine or sertraline. Five weeks later, mice were sacrificed.  
(B) Splenocytes of mice from different experimental groups were co-incubated with YAC-1 cells labeled with [3 H]-thymidine at a target:effector ratio 1:50, 
cultured for 3.5 h and harvested. n = 4 mice per group. (c) Schematic representation of experimental protocol. C57BL/6J mice were treated either with (S) or 
without (C) the chronic stress protocol, and with or without (VEH) fluoxetine or sertraline. Five weeks later, 3 × 106 EL4 cells were subcutaneously injected to 
generate solid tumors. Two weeks post injection (p.i.), mice were sacrificed and spleen cell suspensions were obtained. (D) Specific cytotoxic activity against 
tumor cells was evaluated co-culturing spleen cells suspensions from tumor-bearing mice and labeled EL4 cells with [3H]-thymidine at a target:effector ratio 1:15 
for 3.5 h and harvesting. Percentages of NK or cytotoxic activity were calculated as 100 × (SR − ER)/SR, where SR is the spontaneous release and ER is the 
experimental release. n = 7 mice per group. Values are expressed as mean ± SEM. **p < 0.01 respect to control mice.
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addition, despite MMPs are expressed by multiple cell types in 
tumors, it has been probed that they exert broad pro­tumoral 
functions and their increase in tumors indicate a high­metastatic 
capacity (47). The action of MMPs is partially regulated by TIMPs, 
and the MMPs/TIMP activities balance is relevant for ECM 
turnover (48). Our results showed greater MMP­2 and MMP­9 
and lower TIMP 1, 2, and 3 mRNA levels in tumors from stressed 
animals compared with control. Moreover, cells from tumors of 
stressed animals have a major ability to directionally respond to 
chemoattractants in the transwell migration assays.
FigUre 9 | Evaluation of antitumor immunity role in tumor biological behavior using adoptive cell transfer strategy. (a) Schematic representation of experimental 
protocol. Mice were treated either with (S) or without (C) the chronic stress protocol, and with or without (VEH) fluoxetine or sertraline. Five weeks later, mice were 
sacrificed and lymphoid cells from different experimental groups were tail vein injected in untreated irradiated mice. After 24 h, EL4 cells were subcutaneously 
injected to generate solid tumors. 19 days post subcutaneous injection, mice were sacrificed, and spontaneous metastasis was evaluated. (B) Time course of tumor 
volume for the different experimental groups. (c) Tumor weight at day 19 post EL4 cells injection. (D) Percentage of mice with metastatic nodules in kidney or liver 
(F) was calculated. Also, number of metastatic nodules in kidney (e) or liver (g) was assessed. Values are expressed as mean ± SEM. n = 6 mice per group. 
*p < 0.05, **p < 0.01 respect to control mice.
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It is important to consider that the determinations of cell 
cycle, MMP, and TIMP gene expression levels were performed 
using total tumor RNA. However, it is known that in the tumor 
microenvironment there is a complex variety of cells that 
express these genes. In particular, recent reports demonstrated 
that antigen­specific CD8+ tumor­infiltrating lymphocytes are 
actively pro liferating, but also have a high apoptosis rate (49). 
Moreover, among the innate and adaptive immune cells recruited 
to the tumor site, macrophages are particularly abundant and are 
present at all stages of tumor progression (50). In this context, 
the stress­induced alterations observed in the whole tumor 
could be, at least in part, due to the immune cells from the 
tumor microenvironment. To ascertain if the molecular changes 
took place in cancer cells or in the infiltrating immune cells, we 
performed experiments using tumor cell suspensions depleted 
of the main infiltrating immune cell subsets, namely CD4+ and 
CD8+ T lymphocytes and macrophages (19, 50, 51). Our results 
showed that cell cycle gene expression changes induced by stress 
were similar in both, immune­depleted and not depleted tumor 
cell suspensions. However, a higher increase in MMP­2 expres­
sion levels was found in total tumor cells (% of increase, stressed 
vs control: 169) respect to immune cell­depleted suspensions 
(72%). Non­significant differences were observed in MMP­9 and 
TIMP­1 expression levels. Transwell assay results also indicated 
that the increased migration, induced by stress, of total tumor 
cells was higher than the observed for immune cell­depleted cell 
suspensions (160 vs 72%). Taken together, these results indicate 
that stress­induced tumor growth could be mainly related to 
molecular changes in cancer cells and that the greater invasive 
capacity of tumors from stressed animals is related to molecular 
changes in both cancer and tumor­infiltrating immune cells. 
Noteworthy, fluoxetine treatment reverted the effect of stress 
in both total tumor cell suspensions and immune cell­depleted 
suspensions.
Many findings have suggested a dynamic bidirectional 
dialogue between tumors and the immune system that modu­
lates tumor growth and metastasis (52). The concept of cancer 
immunosurveillance (53) argues that cells of the innate and 
adaptive immune systems eliminate tumor cells thus protecting 
the host against tumor development. However, as cancer pro­
gress, tumor variants that are able to evade immune­mediated 
elimination appear and generate clinically apparent neoplasms. 
This evidence lead to a new assumption, the cancer immunoed­
iting hypothesis, which emphasizes the dual role of immune 
system: host protective and tumor modeling on developing 
tumors (54).
Our results indicate that antitumor immunity was decreased 
in mice submitted to chronic stress. It could be possible to 
pos tulate that stress decreases immune response, thus favoring 
tumor growth. However, due to the unclear performance of the 
immune system in managing solid tumor progression under 
stress situations, the possibility that stress mediators, in particular 
the activation of the sympathetic nervous system, may straightly 
regulate the tumor behavior has been investigated (14, 55). 
Experimental analyses in animal models have found that 
behavioral stress induced an accelerated progression of 
pancreatic (56), prostate (57), breast (58), and ovarian (12) 
carcinomas and malignant melanomas (59). In addition, it 
was demonstrated that the biological action of stress could be 
effectively inhibited by β­adrenergic antagonists and simulated 
by β­agonists (11, 60, 61).
To elucidate if the effects of stress were due to a direct action 
of hormonal stress mediators on tumor cells or an indirect action 
through the alteration of the immune response, we performed an 
adoptive immune cell transfer experiment. Our results indicated 
that when irradiated animals were transferred with immune cells 
from stressed animals, a higher tumor growth and an increased 
number of spontaneous metastasis were observed compared with 
animals transferred with immune cells from control animals. It 
is important to note that irradiated animals were not submitted 
to stress in the whole experiment. These results indicated that, in 
our experimental model, the effect of stress on tumor progression 
was mediated mainly by immune cells.
Finally, our results indicate that fluoxetine or sertraline treat­
ment were able to inhibit the effect of stress on tumor progression. 
Antidepressants are frequently used in cancer patients to treat 
their emotional disorders, such as depression and dysthymia. 
Nevertheless, clinical studies have not revealed clear effects of 
treatment with antidepressant in patients with cancer (62).
Nowadays, there are evidences that suggest that SSRIs could 
be useful in either treating cancer administered alone or in com­
bination with standard chemotherapies (63). In addition, anti­
depressants, and more specifically SSRIs have been shown to 
reduce the risk of certain cancers (64–67). Moreover, these 
antidepressants have been shown to be oncolytic in  vitro and 
in  vivo, through a mechanism that involves an increase of the 
intracellular influx of Ca2+ (68–70) and/or a disruption of the 
mitochondrial membrane potential as well as the generation of 
reactive oxygen species (68, 71, 72). In general, these studies have 
been focalized on the direct action of SSRIs on tumor biology 
without taking into account the effect on antitumor immunity.
Our results emphasize the crucial role of the immune system 
in tumor progression under stress situations. Although a direct 
effect of stress and SSRIs treatment on tumor biology could not be 
TaBle 2 | Effect of chronic stress and fluoxetine treatment on molecular 
changes and migratory ability in immune cell-depleted tumor cells.
c s s Fluoxetine
mRNA expression  
of cell cycle  
proteins
A2 0.999 ± 0.096 2.075 ± 0.376** 1.170 ± 0.117
D1 0.996 ± 0,084 1.688 ± 0.177* 1.076 ± 0.166
p16 1.080 ± 0.181 0.530 ± 0.114* 1.087 ± 0.151
mRNA expression  
of MMPs and  
TIMPs
MMP-2 1.124 ± 0.079 1.927 ± 0.147* 1.290 ± 0.277
MMP-9 1.024 ± 0.204 2.414 ± 0.558* 1.032 ± 0.082
TIMP-1 1.153 ± 0.247 0.341 ± 0.061** 1.110 ± 0.131
Cell migration (%) 5.649 ± 0.905 9.752 ± 1.331* 5.745 ± 0.756
Quantitative real-time reverse transcription polymerase chain reaction was performed 
in cDNA obtained from purified tumor cells suspensions from control (C), stressed (S), 
and fluoxetine-treated stressed (S Fluoxetine) mice. mRNA relative expression was 
quantified using β2-microglobulin as housekeeper. Moreover, isolated cells from solid 
tumors were seeded in the upper well of transwell migration chamber and RPMI with 
10% FBS as attractant. After 24 h, cells in the upper and in the lower chamber were 
counted. Cell migration is presented as percentage of total cell count for each sample. 
Values are expressed as mean ± SEM. n = 5 mice per group. *p < 0.05, **p < 0.01 
respect to control mice.
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